We scan new podcasts and send you the top 5 insights daily.
HRD status is a continuous variable with an arbitrary diagnostic cutoff rather than a strict binary result. When a patient achieves a complete pathological response to neoadjuvant platinum, clinicians consider PARP inhibitors even if formal genomic testing returned negative.
Retrospective data from the PAOLA-one trial shows a significant reduction in benefit from subsequent platinum-based therapy for patients who progressed while on a PARP inhibitor. Objective response rates dropped from 50-60% (placebo group) to 30% (PARP group).
The traditional six-month timeframe for defining platinum sensitivity is being challenged. A growing theory suggests that tumors progressing while on a PARP inhibitor have a distinct biology that responds poorly to subsequent platinum, indicating a potential need to move directly to therapies like ADCs.
Clinicians should view HRD scores as a spectrum rather than a simple positive/negative result. For a patient with a score near the arbitrary cutoff and an excellent clinical response to platinum, oncologists may advocate for insurance coverage of PARP inhibitors.
While PARP inhibitors show some effect in all patients, clinical data revealed a significant survival advantage only in the HRD-positive subgroup. This has led to an FDA restriction, making biomarker testing a prerequisite for this class of drugs.
Inconclusive HRD assays frequently occur following neoadjuvant chemotherapy due to a lack of residual tumor tissue at interval debulking. Rather than indicating an assay failure, the absence of assessable tissue demonstrates an exceptional pathological response to initial systemic treatment.
If multiple attempts at HRD biomarker testing are indeterminate, a strong clinical response to platinum-based neoadjuvant chemotherapy can serve as a surrogate for HRD positivity. This clinical observation can support the decision to treat the patient as HRD-positive and offer a PARP inhibitor.
For HRD-positive ovarian cancer, a strong initial response to platinum chemotherapy may justify using a PARP inhibitor alone for maintenance. A weaker response, however, suggests adding bevacizumab for a potentially greater benefit, using clinical response as a key decision-making tool.
When an HRD test is inconclusive due to insufficient tumor tissue after neoadjuvant chemotherapy, it can paradoxically indicate a very strong response to treatment and high platinum sensitivity, as there is little to no residual tumor to analyze.
The initial broad enthusiasm for PARP inhibitors in ovarian cancer has been refined. New data confirms a lack of overall survival improvement for patients with HRD-negative (or HR proficient) tumors, pushing clinicians toward a precision medicine approach where these drugs are reserved for patients with BRCA mutations or HRD-positive disease who are most likely to benefit.
Giving adjuvant olaparib to BRCA-mutated patients who have already achieved a pathologic complete response (pCR) from neoadjuvant platinum-based chemotherapy is discouraged. Their prognosis is already excellent, so adding a PARP inhibitor offers little potential benefit while exposing them to unnecessary risks of toxicity, such as MDS/AML.